Rexahn Pharmaceuticals Inc.
Fluorocyclopentenyl-cytosine with Broad Spectrum and Potent Antitumor Activity.
(J Med Chem. 2012 May 10;55(9):4521-5. Epub 2012 May 1)[Link]
Synthesis, anticancer activity and pharmacokinetic analysis of 1-[(substituted
2-alkoxyquinoxalin-3-yl)aminocarbonyl]-4-(hetero)arylpiperazine derivatives.
(Bioorganic & Medicinal Chemistry 20 (2012) 1303–1309)[Link]
Synthesis and anticancer activity of new 1-[(5 or 6-substituted 2-alkoxyquinoxalin-3-yl)aminocarbonyl]-4-hetero)arylpiperazine derivatives.
(Bioorganic & Medicinal Chemistry, November 2010, 18(22,15), 7966-7974)[Link]
Development of 3-aryl-1-isoquinolinamines as potent antitumor agents based on CoMFA.
(European Journal of Medicinal Chemistry, November 2010, 45(11), 5493-5497)[Link]
Synthesis, in vitro and in vivo evaluation of 3-arylisoquinolinamines as potent antitumor agents.
(Bioorganic & Medicinal Chemistry Letters, September 2010 20(17,1), 5277-5281)[Link]
Antitumor activity of a novel antisense oligonucleotide against Akt1.
(Journal of Cellular Biochemistry, November 2009, 108(4) 832–838) [Link]
QSID Tool: a new three-dimensional QSAR environmental tool.
(Journal of Computer-Aided Molecular Design, December 2008, 22(12), 873-883)[Link]
In Vivo and In Vitro Effects of a HIF-1a Inhibitor,RX-0047.
(Journal of Cellular Biochemistry, June 2008, 104(3), 985–994)[Link]
SYNTHESIS AND ANTITUMOR ACTIVITY OF FLUOROCYCLOPENTENYL-PYRIMIDINES.
(Nucleosides Nucleotides Nucleic Acids, 2007, 26(6-7), 713-6)[Link]
Requirement of hCenexin for Proper Mitotic Functions of Polo-Like Kinase 1 at the Centrosomes.
(Molecular and Cellular Biology, November 2006, 26(22), 8316-8335)[Link]
Design, synthesis, and anticancer activity of fluorocyclopentenyl-pyrimidines.
(Nucleic Acids Symp Ser, September 2005, 49(1), 107-108)[Link]
